drugset
drugset / Trial / NCT05047523

Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson Disease

NCT05047523 ↗

Phase 3 Terminated 40 enrolled Alexion Pharmaceuticals, Inc.
RandomizedParallel-groupSingle-blindTreatment

Summary

This study is being conducted to evaluate the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics of ALXN1840 versus standard of care in pediatric participants with Wilson disease (WD).

Timeline

Start
2021-09-13
Primary completion
2023-06-26
Completion
2023-06-26

Outcome

Outcome not reported

Stopped (Business): “Sponsor decision to terminate the program”

Drugs

EvaluationDrugModalityDoseRoute
Subject TIOMOLIBDATE CHOLINE Small molecule — Oral
Comparator Zinc Sulfate Unknown — —
Comparator penicillamine Unknown — —
Comparator trientine Unknown — —

Indications

Wilson disease